Collybolide is a novel biased agonist of ê-opioid receptors with potent antipruritic activity

Achla Gupta, Ivone Gomes, Erin N. Bobeck, Amanda K. Fakira, Nicholas P. Massaro, Indrajeet Sharma, Adrien Cavé, Heidi E. Hamm, Joseph Parello, Lakshmi A. Devi, Solomon H Snyder

Research output: Contribution to journalArticle

Abstract

Among the opioid receptors, the κ-opioid receptor (κOR) has been gaining considerable attention as a potential therapeutic target for the treatment of complex CNS disorders including depression, visceral pain, and cocaine addiction. With an interest in discovering novel ligands targeting κOR, we searched natural products for unusual scaffolds and identified collybolide (Colly), a nonnitrogenous sesquiterpene from the mushroom Collybia maculata. This compound has a furyl-δ-lactone core similar to that of Salvinorin A (Sal A), another natural product from the plant Salvia divinorum. Characterization of the molecular pharmacological properties reveals that Colly, like Sal A, is a highly potent and selective κOR agonist. However, the two compounds differ in certain signaling and behavioral properties. Colly exhibits 10- to 50-fold higher potency in activating the mitogen-activated protein kinase pathway compared with Sal A. Taken with the fact that the two compounds are equipotent for inhibiting adenylyl cyclase activity, these results suggest that Colly behaves as a biased agonist of κOR. Behavioral studies also support the biased agonistic activity of Colly in that it exhibits ∼10-fold higher potency in blocking non-histamine-mediated itch compared with Sal A, and this difference is not seen in pain attenuation by these two compounds. These results represent a rare example of functional selectivity by two natural products that act on the same receptor. The biased agonistic activity, along with an easily modifiable structure compared with Sal A, makes Colly an ideal candidate for the development of novel therapeutics targeting κOR with reduced side effects.

Original languageEnglish (US)
Pages (from-to)6041-6046
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume113
Issue number21
DOIs
StatePublished - May 24 2016

Fingerprint

salvinorin A
Antipruritics
Opioid Receptors
Biological Products
Visceral Pain
Salvia
Cocaine-Related Disorders
Sesquiterpenes
Agaricales
Lactones
Mitogen-Activated Protein Kinases
Adenylyl Cyclases
Therapeutics
Pharmacology
Depression
Ligands
Pain

Keywords

  • Antinociception
  • Dynorphin
  • G-protein-coupled receptors
  • Natural compounds
  • Salvinorin A

ASJC Scopus subject areas

  • General

Cite this

Collybolide is a novel biased agonist of ê-opioid receptors with potent antipruritic activity. / Gupta, Achla; Gomes, Ivone; Bobeck, Erin N.; Fakira, Amanda K.; Massaro, Nicholas P.; Sharma, Indrajeet; Cavé, Adrien; Hamm, Heidi E.; Parello, Joseph; Devi, Lakshmi A.; Snyder, Solomon H.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, No. 21, 24.05.2016, p. 6041-6046.

Research output: Contribution to journalArticle

Gupta, A, Gomes, I, Bobeck, EN, Fakira, AK, Massaro, NP, Sharma, I, Cavé, A, Hamm, HE, Parello, J, Devi, LA & Snyder, SH 2016, 'Collybolide is a novel biased agonist of ê-opioid receptors with potent antipruritic activity', Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 21, pp. 6041-6046. https://doi.org/10.1073/pnas.1521825113
Gupta, Achla ; Gomes, Ivone ; Bobeck, Erin N. ; Fakira, Amanda K. ; Massaro, Nicholas P. ; Sharma, Indrajeet ; Cavé, Adrien ; Hamm, Heidi E. ; Parello, Joseph ; Devi, Lakshmi A. ; Snyder, Solomon H. / Collybolide is a novel biased agonist of ê-opioid receptors with potent antipruritic activity. In: Proceedings of the National Academy of Sciences of the United States of America. 2016 ; Vol. 113, No. 21. pp. 6041-6046.
@article{f82cb54746b647a2b2cc623d0316bea9,
title = "Collybolide is a novel biased agonist of {\^e}-opioid receptors with potent antipruritic activity",
abstract = "Among the opioid receptors, the κ-opioid receptor (κOR) has been gaining considerable attention as a potential therapeutic target for the treatment of complex CNS disorders including depression, visceral pain, and cocaine addiction. With an interest in discovering novel ligands targeting κOR, we searched natural products for unusual scaffolds and identified collybolide (Colly), a nonnitrogenous sesquiterpene from the mushroom Collybia maculata. This compound has a furyl-δ-lactone core similar to that of Salvinorin A (Sal A), another natural product from the plant Salvia divinorum. Characterization of the molecular pharmacological properties reveals that Colly, like Sal A, is a highly potent and selective κOR agonist. However, the two compounds differ in certain signaling and behavioral properties. Colly exhibits 10- to 50-fold higher potency in activating the mitogen-activated protein kinase pathway compared with Sal A. Taken with the fact that the two compounds are equipotent for inhibiting adenylyl cyclase activity, these results suggest that Colly behaves as a biased agonist of κOR. Behavioral studies also support the biased agonistic activity of Colly in that it exhibits ∼10-fold higher potency in blocking non-histamine-mediated itch compared with Sal A, and this difference is not seen in pain attenuation by these two compounds. These results represent a rare example of functional selectivity by two natural products that act on the same receptor. The biased agonistic activity, along with an easily modifiable structure compared with Sal A, makes Colly an ideal candidate for the development of novel therapeutics targeting κOR with reduced side effects.",
keywords = "Antinociception, Dynorphin, G-protein-coupled receptors, Natural compounds, Salvinorin A",
author = "Achla Gupta and Ivone Gomes and Bobeck, {Erin N.} and Fakira, {Amanda K.} and Massaro, {Nicholas P.} and Indrajeet Sharma and Adrien Cav{\'e} and Hamm, {Heidi E.} and Joseph Parello and Devi, {Lakshmi A.} and Snyder, {Solomon H}",
year = "2016",
month = "5",
day = "24",
doi = "10.1073/pnas.1521825113",
language = "English (US)",
volume = "113",
pages = "6041--6046",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "21",

}

TY - JOUR

T1 - Collybolide is a novel biased agonist of ê-opioid receptors with potent antipruritic activity

AU - Gupta, Achla

AU - Gomes, Ivone

AU - Bobeck, Erin N.

AU - Fakira, Amanda K.

AU - Massaro, Nicholas P.

AU - Sharma, Indrajeet

AU - Cavé, Adrien

AU - Hamm, Heidi E.

AU - Parello, Joseph

AU - Devi, Lakshmi A.

AU - Snyder, Solomon H

PY - 2016/5/24

Y1 - 2016/5/24

N2 - Among the opioid receptors, the κ-opioid receptor (κOR) has been gaining considerable attention as a potential therapeutic target for the treatment of complex CNS disorders including depression, visceral pain, and cocaine addiction. With an interest in discovering novel ligands targeting κOR, we searched natural products for unusual scaffolds and identified collybolide (Colly), a nonnitrogenous sesquiterpene from the mushroom Collybia maculata. This compound has a furyl-δ-lactone core similar to that of Salvinorin A (Sal A), another natural product from the plant Salvia divinorum. Characterization of the molecular pharmacological properties reveals that Colly, like Sal A, is a highly potent and selective κOR agonist. However, the two compounds differ in certain signaling and behavioral properties. Colly exhibits 10- to 50-fold higher potency in activating the mitogen-activated protein kinase pathway compared with Sal A. Taken with the fact that the two compounds are equipotent for inhibiting adenylyl cyclase activity, these results suggest that Colly behaves as a biased agonist of κOR. Behavioral studies also support the biased agonistic activity of Colly in that it exhibits ∼10-fold higher potency in blocking non-histamine-mediated itch compared with Sal A, and this difference is not seen in pain attenuation by these two compounds. These results represent a rare example of functional selectivity by two natural products that act on the same receptor. The biased agonistic activity, along with an easily modifiable structure compared with Sal A, makes Colly an ideal candidate for the development of novel therapeutics targeting κOR with reduced side effects.

AB - Among the opioid receptors, the κ-opioid receptor (κOR) has been gaining considerable attention as a potential therapeutic target for the treatment of complex CNS disorders including depression, visceral pain, and cocaine addiction. With an interest in discovering novel ligands targeting κOR, we searched natural products for unusual scaffolds and identified collybolide (Colly), a nonnitrogenous sesquiterpene from the mushroom Collybia maculata. This compound has a furyl-δ-lactone core similar to that of Salvinorin A (Sal A), another natural product from the plant Salvia divinorum. Characterization of the molecular pharmacological properties reveals that Colly, like Sal A, is a highly potent and selective κOR agonist. However, the two compounds differ in certain signaling and behavioral properties. Colly exhibits 10- to 50-fold higher potency in activating the mitogen-activated protein kinase pathway compared with Sal A. Taken with the fact that the two compounds are equipotent for inhibiting adenylyl cyclase activity, these results suggest that Colly behaves as a biased agonist of κOR. Behavioral studies also support the biased agonistic activity of Colly in that it exhibits ∼10-fold higher potency in blocking non-histamine-mediated itch compared with Sal A, and this difference is not seen in pain attenuation by these two compounds. These results represent a rare example of functional selectivity by two natural products that act on the same receptor. The biased agonistic activity, along with an easily modifiable structure compared with Sal A, makes Colly an ideal candidate for the development of novel therapeutics targeting κOR with reduced side effects.

KW - Antinociception

KW - Dynorphin

KW - G-protein-coupled receptors

KW - Natural compounds

KW - Salvinorin A

UR - http://www.scopus.com/inward/record.url?scp=84971469242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971469242&partnerID=8YFLogxK

U2 - 10.1073/pnas.1521825113

DO - 10.1073/pnas.1521825113

M3 - Article

VL - 113

SP - 6041

EP - 6046

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 21

ER -